AXQ Capital LP Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

AXQ Capital LP purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 4th quarter, HoldingsChannel reports. The firm purchased 1,644 shares of the biopharmaceutical company’s stock, valued at approximately $387,000.

Several other large investors also recently bought and sold shares of the stock. American Century Companies Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 0.7% in the 4th quarter. American Century Companies Inc. now owns 1,604,024 shares of the biopharmaceutical company’s stock valued at $377,443,000 after acquiring an additional 11,291 shares during the last quarter. Quantbot Technologies LP increased its holdings in shares of Alnylam Pharmaceuticals by 678.4% in the 4th quarter. Quantbot Technologies LP now owns 1,588 shares of the biopharmaceutical company’s stock valued at $374,000 after acquiring an additional 1,384 shares during the last quarter. Blueshift Asset Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 59.1% in the 4th quarter. Blueshift Asset Management LLC now owns 1,698 shares of the biopharmaceutical company’s stock valued at $400,000 after acquiring an additional 631 shares during the last quarter. Teacher Retirement System of Texas increased its holdings in shares of Alnylam Pharmaceuticals by 16.1% in the 4th quarter. Teacher Retirement System of Texas now owns 39,075 shares of the biopharmaceutical company’s stock valued at $9,195,000 after acquiring an additional 5,425 shares during the last quarter. Finally, Royal London Asset Management Ltd. increased its holdings in shares of Alnylam Pharmaceuticals by 0.6% in the 4th quarter. Royal London Asset Management Ltd. now owns 281,509 shares of the biopharmaceutical company’s stock valued at $66,242,000 after acquiring an additional 1,759 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 11.8 %

ALNY opened at $283.34 on Monday. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The business has a 50 day simple moving average of $257.16 and a 200-day simple moving average of $259.74. The stock has a market capitalization of $36.68 billion, a P/E ratio of -130.57 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. JPMorgan Chase & Co. increased their price objective on Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the company a “neutral” rating in a report on Tuesday, March 11th. Chardan Capital restated a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Friday. Wells Fargo & Company raised their price target on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an “equal weight” rating in a research note on Friday. Finally, Scotiabank raised their price target on Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the stock a “sector outperform” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $310.22.

Insider Buying and Selling

In related news, CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the transaction, the chief executive officer now directly owns 81,526 shares of the company’s stock, valued at approximately $20,802,989.42. The trade was a 1.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.